Disclosing Deliberations on Calculation of NHI Prices - A Succession of Opinions Calling for Transparency

株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

【Administrative Review for MHLW】 
Disclosing Deliberations on Calculation of NHI Prices - A Succession of Opinions Calling for Transparency
November 18th, 2020

On November 15, 2020, at the government's administrative reform promotion council's "Autumn Administrative Project Review" to review the wastefulness of the budget, the Ministry of Health, Labor and Welfare (MHLW) announced its intention to disclose the outline of the deliberations, the list of committee members, and the like of the NHI pricing organization that calculates the specific NHI prices of approved prescription drugs.  Although the MHLW does not currently disclose them in principle from the perspective of protection of trade secrets, it announced that it would take actions after a succession of opinions from evaluators calling for ensuring transparency.  The reasons will be explained if they are not to be disclosed.

(Continue to the next)

For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2020 LSMIP office / CM Plus Singapore Pte. Ltd.